Verona Pharma (VRNA) Revenue & Revenue Breakdown
Verona Pharma Revenue Highlights
0
Latest Revenue (Q)
$5.62M
Verona Pharma Revenue by Period
Verona Pharma Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $458.00K | -98.86% |
| 2021-12-31 | $40.00M | 100.00% |
| 2020-12-31 | - | -100.00% |
| 2019-12-31 | $2.35K | -15.52% |
| 2018-12-31 | $2.78K | -99.85% |
| 2017-12-31 | $1.84M | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2011-12-31 | - | 100.00% |
| 2010-12-31 | - | 100.00% |
| 2009-12-31 | - | 100.00% |
| 2008-12-31 | - | 100.00% |
| 2007-12-31 | - | 100.00% |
| 2006-12-31 | - | 100.00% |
| 2005-12-31 | - | - |
Verona Pharma generated - in revenue during NA 2023, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Verona Pharma Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $5.62M | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $940.06K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | -100.00% |
| 2022-12-31 | $458.00K | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | -100.00% |
| 2021-09-30 | $40.00M | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | -100.00% |
| 2019-12-31 | $2.35K | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | -100.00% |
| 2018-12-31 | $2.78K | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | -100.00% |
| 2017-12-31 | $1.84M | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2005-06-30 | - | - |
Verona Pharma generated $5.62M in revenue during Q3 2024, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Verona Pharma Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AMLX | Amylyx Pharmaceuticals | $380.79M | $416.00K |
| APLS | Apellis Pharmaceuticals | $366.28M | $176.57M |
| PTGX | Protagonist Therapeutics | $60.00M | $4.67M |
| IDYA | IDEAYA Biosciences | $23.39M | - |
| MREO | Mereo BioPharma Group | $10.00M | - |
| XFOR | X4 Pharmaceuticals | - | $560.00K |
| VKTX | Viking Therapeutics | - | - |
| DAWN | Day One Biopharmaceuticals | - | $20.07M |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| VRNA | Verona Pharma | - | $5.62M |
| MDGL | Madrigal Pharmaceuticals | - | $62.17M |
| SNDX | Syndax Pharmaceuticals | - | $12.50M |
| TERN | Terns Pharmaceuticals | - | - |
| VTYX | Ventyx Biosciences | - | - |
| AKRO | Akero Therapeutics | - | - |
| MLTX | MoonLake Immunotherapeutics | - | - |